chlorotrianisene (tace) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Chlorotrianisene (TACE®) is a powerful synthetic, non-steroidal estrogen used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. It may also be used to prevent breast engorgement following childbirth. Chlorotrianisene (TACE®) binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.   NCATS

Chemistry

  • SMILES: COC1=CC=C(C=C1)C(Cl)=C(C2=CC=C(OC)C=C2)C3=CC=C(OC)C=C3
  • InChIKey: BFPSDSIWYFKGBC-UHFFFAOYSA-N
  • Mol. Mass: 380.864
  • ALogP: 5.87
  • ChEMBL Molecule:
    chlorotrianisene  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

chloortrianisestrol | chlorestrolo | chlorotrianisene | chlorotrianisenum | chlorotrianisine | chlorotrianizen | chlortrianisen | chlortrianisestrol | chlortrianisoestrolum | chlortrianizen | clorotrianisene | clorotrianiseno | clorotrisin | hormonisene | khlortrianizen | tace | trianisestrol

Organizations (16)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (4)


 

Breast Diseases

Infertility, Female

Menopause

Prostatic Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Carcinoma, Hepatocellular (Phase 2)

Cholangiocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 3)

Liver Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue